ESMO 2023 Lung Cancer Highlights – Keynote 671, ALINA, TropionLung01

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss:

– Keynote 671 – perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data

– ALINA – resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS

– TropionLung 01 – Dato-DXd in 2nd line non-small cell lung cancer reports slightly greater PFS when compared to docetaxel

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology